| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary target of Deltarasin is phosphodiesterase delta (PDEδ), specifically the hydrophobic pocket that binds KRAS. It acts as a high-affinity inhibitor of the KRAS-PDEδ interaction with a Kd of 38 nM. By blocking this interaction, it impairs KRAS localization to the plasma membrane and inhibits RAS/RAF signaling.
|
|---|---|
| ln Vitro |
In liver cells, Deltarasin inhibits the interaction of RAS with PDEδ with KD of 41 nM. Inhibition of PDEδ-KRAS interaction by Deltarasin suppresses proliferation of human pancreatic ductal adenocarcinoma cells that are dependent on oncogenic KRAS.
Kinase Assay: Kd values are measured by fluorescence polarization measurements. For direct titrations, increasing amounts of PDEδ are added to a solution containing 50-100 nM labelled small molecule in 200 µL PBS buffer. For displacement titrations, increasing amounts of the small molecules in DMSO are directly added to fluorescein-labelled atorvastatin (24 nM) and His6-tagged PDEδ (40 nM) in 200 µL PBS-buffer (containing 0.05% CHAPS, 1% DMSO), keeping the concentration of fluorescein-labelled atorvastatin, PDEδ and DMSO constant. For Kd measurements using isothermal titration calorimetry, PDEδ protein (280 µM) is titrated to small molecule (30 µM) in Tris/HCl buffer (temperature 25°C). In the Tm shift assays, protein melting points are detected by circular dichroism spectroscopy in the presence of small molecules. Cell Assay: Within a minute, 5 mM of deltarasin completely inhibited PDEδ-KRAS interaction and released the insolubilized mCitrine-RHEB/KRAS6Q to the endomembrane system. This showed that deltarasin interfered with the binding of KRAS to PDEδ in cells and thereby inhibited its solubilization. Deltarasin binds to PDEδ with a Kd of 38 nM. It inhibits the KRAS-PDEδ interaction, leading to impaired cell growth, KRAS activity, and RAS/RAF signaling in human pancreatic ductal adenocarcinoma cell lines. Its anti-cancer cell activity can be enhanced by simultaneously blocking tumor-protective autophagy. |
| ln Vivo |
Deltarasin (10 mg/kg i.p.) impairs dose-dependent tumor growth in nude mice bearing subcutaneous human Panc-Tu-I tumour cell xenografts.
In vivo data for Deltarasin are limited. The compound is primarily characterized in in vitro systems. Its potent inhibition of KRAS-PDEδ interaction and anti-cancer activity in pancreatic cancer cell lines warrant further in vivo investigation. Detailed pharmacokinetic and efficacy data in animal models are not extensively documented. |
| Enzyme Assay |
For non-cellular binding studies, recombinant PDEδ is incubated with Deltarasin in the presence of a fluorescently labeled KRAS probe. Binding affinity is measured by fluorescence polarization or surface plasmon resonance. The Kd value is determined to be 38 nM.
|
| Cell Assay |
In vitro cell experiments employ human pancreatic ductal adenocarcinoma cell lines. Deltarasin is added, and cell growth is measured by MTT assays. KRAS activity and RAS/RAF signaling are assessed by Western blotting for phosphorylated ERK. These protocols are for reference use only.
|
| Animal Protocol |
Dissolved in 10% PLR and 5% DMSO; 10 mg/kg; Administered through i.p.Mice bearing Panc-Tu-I xenografts
Animal studies for Deltarasin are limited. The compound is primarily characterized in in vitro systems. Detailed pharmacokinetic and efficacy data in animal models are not extensively documented. All products are for research use only. |
| References |
| Molecular Formula |
C40H40CL3N5O
|
|---|---|
| Molecular Weight |
713.144
|
| Exact Mass |
639.276
|
| CAS # |
1440898-82-7
|
| Related CAS # |
Deltarasin;1440898-61-2;Deltarasin hydrochloride;1613404-76-4
|
| PubChem CID |
73292904
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.8
|
| tPSA |
56.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
46
|
| Complexity |
923
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].Cl[H].Cl[H].O(C1C([H])=C([H])C(C2=NC3=C([H])C([H])=C([H])C([H])=C3N2C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])=C([H])C=1[H])C([H])([H])[C@]([H])(C1([H])C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])N1C(C2C([H])=C([H])C([H])=C([H])C=2[H])=NC2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
NCIOVAYUMQEQEU-VKZSUDIWSA-N
|
| InChi Code |
InChI=1S/C40H37N5O.3ClH/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31/h1-22,30,38,41H,23-28H23*1H/t38-/m1.../s1
|
| Chemical Name |
2-[4-[(2S)-2-(2-phenyl-1H-benzimidazol-1-yl)-2-(4-piperidinyl)ethoxy]phenyl]-1-(phenylmethyl)-1H-benzimidazole, trihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4022 mL | 7.0112 mL | 14.0225 mL | |
| 5 mM | 0.2804 mL | 1.4022 mL | 2.8045 mL | |
| 10 mM | 0.1402 mL | 0.7011 mL | 1.4022 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.